TransMedics Group, Inc. (TMDX)

NASDAQ: TMDX · IEX Real-Time Price · USD
56.91
+2.04 (3.72%)
At close: Sep 27, 2023, 4:00 PM
57.34
+0.43 (0.76%)
After-hours: Sep 27, 2023, 6:55 PM EDT
3.72%
Market Cap 1.86B
Revenue (ttm) 151.08M
Net Income (ttm) -17.78M
Shares Out 32.63M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 454,097
Open 55.21
Previous Close 54.87
Day's Range 55.18 - 57.16
52-Week Range 38.86 - 99.63
Beta 1.46
Analysts Buy
Price Target 89.60 (+57.44%)
Earnings Date Nov 2, 2023

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for dou... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 2, 2019
Employees 212
Stock Exchange NASDAQ
Ticker Symbol TMDX
Full Company Profile

Financial Performance

In 2022, TMDX's revenue was $93.46 million, an increase of 208.83% compared to the previous year's $30.26 million. Losses were -$36.23 million, -18.06% less than in 2021.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $89.6, which is an increase of 57.44% from the latest price.

Price Target
$89.6
(57.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

ANDOVER, Mass. , Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

4 weeks ago - PRNewsWire

TransMedics Completes Acquisition of Summit Aviation

ANDOVER, Mass. , Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

6 weeks ago - PRNewsWire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Aug. 7, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

7 weeks ago - PRNewsWire

TransMedics Reports Second Quarter 2023 Financial Results

ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

7 weeks ago - PRNewsWire

Bridge to Life Divests Certain Assets to TransMedics

NORTHBROOK, Ill. , Aug. 2, 2023 /PRNewswire/ -- Bridge to Life Ltd.

2 months ago - PRNewsWire

TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life

ANDOVER, Mass. , Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

2 months ago - PRNewsWire

TransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation

Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S. ANDOVER, Mass. , Aug. 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: T...

2 months ago - PRNewsWire

TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

2 months ago - PRNewsWire

TransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference

ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

2 months ago - PRNewsWire

TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023

ANDOVER, Mass. , July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

2 months ago - PRNewsWire

TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028

ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

5 months ago - PRNewsWire

TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028

ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

5 months ago - PRNewsWire

TransMedics Reports First Quarter 2023 Financial Results

ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

5 months ago - PRNewsWire

TransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report

ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...

5 months ago - PRNewsWire

TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today anno...

5 months ago - PRNewsWire

TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results

ANDOVER, Mass. , Feb. 22, 2023 /PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

7 months ago - PRNewsWire

TransMedics to Present at Upcoming March Investor Conferences

ANDOVER, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

7 months ago - GlobeNewsWire

TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

ANDOVER, Mass. , Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

8 months ago - PRNewsWire

TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations

ANDOVER, Mass. , Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

8 months ago - PRNewsWire

TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

ANDOVER, Mass. , Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

10 months ago - PRNewsWire

TransMedics Reports Third Quarter 2022 Financial Results

Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment 2022 Revenue Guidance Range Raised to $ 80 million to $85 million ANDOVER, Mass. , Nov. ...

11 months ago - PRNewsWire

TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022

ANDOVER, Mass. , Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

1 year ago - PRNewsWire

CIBC Innovation Banking Provides $60 Million Debt Financing to TransMedics Group Inc.

BOSTON--(BUSINESS WIRE)--CIBC Innovation Banking is pleased to announce a new debt financing for Massachusetts-based TransMedics Group, Inc. ("TransMedics"), a market leading medical technology compan...

1 year ago - Business Wire

TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

ANDOVER, Mass. , Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...

1 year ago - PRNewsWire

TransMedics Announces Upsize and Pricing of Public Offering of Common Stock

ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...

1 year ago - PRNewsWire